Which study demonstrated superior outcomes for Suprathel compared with Biobrane in pediatric partial‑thickness burns after tangential excision?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Suprathel Demonstrates Superior Outcomes Compared to Biobrane in Pediatric Partial-Thickness Burns

Suprathel is associated with significantly better outcomes than Biobrane for pediatric partial-thickness burns, with shorter hospital stays (4 vs 9 days), lower rates of escharectomy and grafting (21.1% vs 32.1%), and reduced need for long-term reintervention (18.5% vs 26.2%). 1

Key Outcome Differences

The 2024 European Journal of Pediatrics study 1 provides the most direct head-to-head comparison and demonstrates clear superiority of Suprathel across multiple clinically meaningful endpoints:

Hospital Length of Stay

  • Suprathel: Median 4 days (IQR 2-9)
  • Biobrane: Median 9 days (IQR 7-14)
  • This represents a 56% reduction in hospitalization time

Acute Management Outcomes

  • Escharectomy and grafting rate during acute phase:
    • Suprathel: 21.1%
    • Biobrane: 32.1%
    • This 11% absolute difference indicates better preservation of viable tissue with Suprathel

Long-Term Quality of Life Impact

  • Reintervention rate at follow-up:
    • Suprathel: 18.5%
    • Biobrane: 26.2%
    • The lower reintervention rate suggests better functional and aesthetic outcomes, directly impacting long-term quality of life

Study Quality and Applicability

The comparative study 1 included 378 pediatric patients (92 Suprathel, 107 Biobrane, 179 EZ-derm) with no significant differences in baseline demographics or burn characteristics between groups, making the comparison valid. This retrospective cohort from 2015-2021 represents contemporary practice patterns.

Important caveat: While Biobrane shows efficacy compared to traditional dressings—with one 2025 meta-analysis 2 demonstrating 5.2 days faster healing and 2 days shorter hospital stays versus standard dressings—these benefits are modest compared to Suprathel's performance.

Clinical Implications for Morbidity and Mortality

The reduced need for escharectomy and grafting with Suprathel (21.1% vs 32.1%) has direct implications for:

  • Reduced surgical morbidity (fewer anesthetic exposures, less blood loss)
  • Lower infection risk (fewer invasive procedures)
  • Better cosmetic outcomes (preservation of native tissue when possible)
  • Reduced psychological trauma (fewer procedures, shorter hospitalization)

Practical Considerations

A 2025 study 3 identified risk factors for premature Suprathel detachment:

  • Patient age (younger children at higher risk)
  • Burn location (certain anatomical sites more problematic)
  • Correlation with burn depth progression

Despite these limitations, only 13% of patients required surgical revision after material detachment, and the overall outcomes remained superior to alternatives.

Algorithm for Decision-Making

For pediatric partial-thickness burns after tangential excision, use Suprathel as first-line treatment based on:

  1. Superior reduction in hospital stay (prioritizes family burden and healthcare costs)
  2. Lower grafting requirements (reduces surgical morbidity)
  3. Decreased long-term reintervention needs (improves quality of life)

Reserve Biobrane for situations where Suprathel is unavailable or cost-prohibitive, as it still outperforms traditional dressings but provides inferior outcomes compared to Suprathel.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.